Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy

Inclusion Criteria: * Age ≥ 18 years old. * Patients enrolled at INCA with a diagnosis of cell carcinoma squamous, adenoid cystic carcinoma, mucoepidermoid carcinoma, carcinoma of acinar cells, low-grade polymorph adenocarcinoma, located in the oral cavity (ICD-10 C00 to C06); located in the oral cavity with the indication of exclusive radiotherapy (by IMRT/VMAT technique) or radiotherapy (by IMRT/ VMAT) associated with chemotherapy. * Performance status (PS) 0 or 1. * Patients with intact oral mucosa (except the tumor area) without color change and volume on the first day of treatment. * Patients able to cooperate with treatment. * Patients capable of performing the oral hygiene protocol. * Patients who after the information and instructions signed the term of free and informed consent of the patient in accordance with Resolution 466/12 of the National Health Council. Exclusion Criteria: * Patients who are receiving drugs for the treatment and/or prevention of oral mucositis. * Patients undergoing radiotherapy with planning that excludes the oral cavity of the treatment field. * Patients undergoing palliative radiotherapy. * Patients with cervical lymph node metastasis greater than 6cm (N3). * Patients who report any type of allergy to copaiba-based compounds. * Patients diagnosed with oral lichen planus.